Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NeuroMed Pharmaceuticals

Request full access

Calcium channel blockers for chronic pain treatment

New Haven, United StatesFounded 1998Outside Tech

About NeuroMed Pharmaceuticals

NeuroMed Pharmaceuticals was a biopharmaceutical company focused on developing treatments for chronic pain by targeting calcium channels. The company was founded in 1998 in Vancouver, Canada, by Dr. Terrance Snutch, a professor at the University of British Columbia. NeuroMed operated on a "fusion" business model, which combined high-risk, high-reward drug discovery with lower-risk specialty pharmaceutical development.

The company's research focused on developing N-type and T-type calcium channel blockers to treat chronic pain, epilepsy, and hypertension. One of its key product candidates was NMED-1077, also known as OROS Hydromorphone, a once-daily, extended-release formulation of hydromorphone for chronic moderate-to-severe pain. NeuroMed acquired the U.S. rights for this product from Johnson & Johnson's subsidiary, ALZA Corporation, and advanced it to Phase 3 clinical trials. Additionally, NeuroMed had a research collaboration with Merck to discover novel compounds targeting N-type calcium channels, though this partnership was terminated in 2009 after the molecules developed did not meet the criteria for human clinical trials.

Throughout its operation, NeuroMed secured significant funding, raising a total of $126 million over several financing rounds, with its Series E round in 2007 raising $53.3 million. Key investors included MPM Capital, GrowthWorks Capital, Royal Bank of Canada, and BDC Venture Capital. The company was formerly known as Neuromed Technologie before changing its name in March 2006. Ultimately, Neuromed Pharmaceuticals was acquired and is now considered a deadpooled company.

Source: Dealroom company data

NeuroMed Pharmaceuticals in the New Haven ecosystem

Live from Dealroom

The NeuroMed Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • MDS Capital

Series B and later5 investors entered at this stage

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New Haven HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NeuroMed Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeuroMed Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.